Lataa…
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
Päätekijät: | , , , , , , , , , , |
---|---|
Aineistotyyppi: | Online Artikkeli Teksti |
Kieli: | English |
Julkaistu: |
Nature Publishing Group UK
2018
|
Aiheet: | |
Linkit: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809482/ https://www.ncbi.nlm.nih.gov/pubmed/29434192 http://dx.doi.org/10.1038/s41408-018-0055-x |